Company news
Celldex Therapeutics, Inc. news in 2024
Celldex Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
December 18, 2024
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
November 19, 2024
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 5, 2024
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
October 25, 2024
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
October 24, 2024
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
September 24, 2024
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
September 15, 2024
Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 7, 2024
Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
July 28, 2024
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
July 15, 2024
Celldex Therapeutics to Present at Jefferies Healthcare Conference
June 3, 2024
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
June 1, 2024
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
May 14, 2024
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 5, 2024
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
April 16, 2024
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
March 7, 2024
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
March 4, 2024
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 4, 2024
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
February 28, 2024
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
February 27, 2024
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
February 25, 2024
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
February 23, 2024
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 5, 2024
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
February 4, 2024
Decks in 2024
- European Academy of Dermatology and Venereology (EADV 2024)
Conference · 16 slides · 2024